Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alnylam Pharmaceuticals Inc announces acquisition of Merck & Co Inc's wholly owned subsidiary Sirna Therapeutics Inc


Sunday, 12 Jan 2014 09:00pm EST 

Alnylam Pharmaceuticals Inc:Says the acquisition of Merck & Co Inc's wholly owned subsidiary Sirna Therapeutics Inc, comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.Says under the agreement, in exchange for acquiring the stock of Sirna Therapeutics, Alnylam will pay Merck an upfront payment of $175 mln in cash and equity ($25 mln cash/$150 mln in Alnylam common stock).Says in addition, Merck is eligible to receive up to $105 mln in developmental and sales milestone payments per product, as well as single-digit royalties, associated with the progress of certain pre-clinical candidates discovered by Merck.Says Merck is also eligible to receive up to $10 mln in milestone payments and single-digit royalties on Alnylam products covered by Sirna Therapeutics' patent estate. 

Company Quote

59.58
0.6 +1.02%
19 Dec 2014